DNA Repair Polymorphisms in Glioblastoma Susceptibility

Irene Rodriguez-Hernandez1,2,3 and Rogelio Gonzalez-Sarmiento1,2
1Molecular Medicine Unit, Department of Medicine, University of Salamanca, Salamanca, Spain
2IBMC and IBSAL, USAL/CSIC/University Hospital, Salamanca, Spain
3Tumour Plasticity Laboratory, Randall Division of Cell and Molecular Biophysics, King’s College London, London, United Kingdom

Corresponding author: Rogelio Gonzalez-Sarmiento, Molecular Medicine Unit, Department of Medicine, University of Salamanca. C/ Alfonso X El Sabio, s/n, Campus Miguel de Unamuno, 37007, Salamanca, Spain, Tel: 34 923294553, Fax: 34 923294593; E-mail: gonzalez@usal.es

Received date: March 15, 2016; Accepted date: March 31, 2016; Published date: April 5, 2016

Copyright: ©2016 Rodriguez-Hernandez I, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Glioblastoma accounts for about 70% of gliomas and is the most common and aggressive primary malignant brain tumour in adults [1]. Despite the better understanding of glioma biology and the improvements in therapeutic approaches, patients diagnosed with glioblastoma have a median survival of only 12-14 months [2]. Although several alterations in core signalling pathways have been identified in glioblastoma, the aetiology of most of glioblastoma cases is still poorly understood [2].

DNA repair function is critical in maintaining genome stability and integrity. Thus, deficiencies in DNA repair capability may affect susceptibility to cancer [6]. Several polymorphisms in DNA repair genes have been associated with small variations in the efficacy of DNA repair that may facilitate glioma development [7-10]. However, in many cases these association studies have yield inconclusive results due to insufficient sample sizes, differences in population ethnicity or environmental exposure, or even they might be influenced by possible gene-environment interactions [11]. In addition, most of the studies investigated mixed histologic subtypes of glioma with different genetic background (low-grade astrocytomas, anaplastic astrocytomas, glioblastomas and oligodendrogliomas), and only a few studies have specifically evaluated the relation of DNA repair polymorphism in glioblastoma susceptibility.

In that regard, the article by Rodriguez-Hernandez and colleagues [12] investigated the role of several common polymorphisms in relevant genes to four major DNA repair pathways in modulating glioblastoma risk. The authors showed that the homozygous Gln/Gln genotype of ERCC2 rs13181 polymorphism was associated with a protective effect of developing glioblastoma. Moreover, the authors found that the haplotype containing the C allele of ERCC2 rs13181 polymorphism and the T allele of ERCC1 rs11615 polymorphism was significantly associated with a protective effect of developing glioblastoma [12]. Both ERCC2 and ERCC1 genes are involved in the same DNA repair pathway, the nucleotide excision repair (NER) pathway, and are located on the same chromosomal region (19q13.32), suggesting that they may have a collective effect on DNA repair outcome and the 19q chromosomal region could be important in glioblastoma pathogenesis. This is supported by the fact that different expression profiles and copy number alterations in this region have been found in familial and sporadic gliomas and are also related to glioma patients’ survival [3,13-15]. However, although the ERCC2 rs13181 polymorphism is one of the most studied polymorphisms in ERCC2 gene, its functional significance is still not clear [16-18] and its association with glioma, and in particular with glioblastoma risk, is also controversial [7-9,19-22].

In conclusion, their results pointed out that both ERCC2 rs13181 and MLH1 rs1800734 polymorphisms might constitute glioblastoma susceptibility factors, although more studies in larger glioblastoma populations with functional studies are needed to validate the role of these polymorphisms in glioblastoma development. The identification of genetic and molecular biomarkers is critical for shedding light on the complex pathogenesis of glioblastoma tumours and might improve early diagnosis and/or help in the development of personalized therapies for these patients with a dismal prognosis.

References


